TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Aim-to conduct a randomized clinical intervention study to compare three diets (low-fat, low-carbohydrate and Mediterranean diet) for weight loss


Options:
A: Arm Label: Intervention; Type: N/A; Interventions: Behavioral: educational/counseling intervention, Behavioral: therapeutic dietary intervention | Arm Label: Control; Type: N/A; Interventions: Behavioral: therapeutic dietary intervention | Intervention Type: BEHAVIORAL; Name: educational/counseling intervention; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: therapeutic dietary intervention; Assigned to Arm(s): Control, Intervention
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Low-fat, low-Glycemic Index, vegan diet | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Low-fat, low-Glycemic Index, vegan diet | Intervention Type: BEHAVIORAL; Name: Low-fat, low-Glycemic Index, vegan diet; Assigned to Arm(s): 1, 2
C: Intervention Type: BEHAVIORAL; Name: dietary intervention; Assigned to Arm(s): N/A
D: Arm Label: low fat hypocaloric diet; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: dietary intervention | Arm Label: Low carbohydrate hypocaloric diet; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: dietary intervention | Intervention Type: BEHAVIORAL; Name: dietary intervention; Assigned to Arm(s): Low carbohydrate hypocaloric diet, low fat hypocaloric diet

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Aim-to conduct a randomized clinical intervention study to compare three diets (low-fat, low-carbohydrate and Mediterranean diet) for weight loss


Options:
A: Intervention Type: BEHAVIORAL; Name: dietary intervention; Assigned to Arm(s): N/A
B: Intervention Type: BEHAVIORAL; Name: Paleolithic diet; Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: low glycemic load diet; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: low fat diet; Assigned to Arm(s): N/A
D: Arm Label: High fat low carbohydrate diet; Type: EXPERIMENTAL; Interventions: Dietary Supplement: High fat low carbohydrate diet | Arm Label: Low fat high carbohydrate diet; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Low fat high carbohydrate diet | Intervention Type: DIETARY_SUPPLEMENT; Name: High fat low carbohydrate diet; Assigned to Arm(s): High fat low carbohydrate diet | Intervention Type: DIETARY_SUPPLEMENT; Name: Low fat high carbohydrate diet; Assigned to Arm(s): Low fat high carbohydrate diet

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Aim-to conduct a randomized clinical intervention study to compare three diets (low-fat, low-carbohydrate and Mediterranean diet) for weight loss


Options:
A: Intervention Type: BEHAVIORAL; Name: diet, sodium-restricted; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: exercise; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, reducing; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: alcohol drinking; Assigned to Arm(s): N/A
B: Intervention Type: BEHAVIORAL; Name: dietary intervention; Assigned to Arm(s): N/A
C: Arm Label: Intervention; Type: N/A; Interventions: Behavioral: educational/counseling intervention, Behavioral: therapeutic dietary intervention | Arm Label: Control; Type: N/A; Interventions: Behavioral: therapeutic dietary intervention | Intervention Type: BEHAVIORAL; Name: educational/counseling intervention; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: therapeutic dietary intervention; Assigned to Arm(s): Control, Intervention
D: Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Aim-to conduct a randomized clinical intervention study to compare three diets (low-fat, low-carbohydrate and Mediterranean diet) for weight loss


Options:
A: Intervention Type: BEHAVIORAL; Name: dietary intervention; Assigned to Arm(s): N/A
B: Arm Label: weight loss surgery; Type: EXPERIMENTAL; Interventions: Procedure: laparoscopic sleeve gastrectomy | Arm Label: Lifestyle Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: weight management program | Intervention Type: PROCEDURE; Name: laparoscopic sleeve gastrectomy; Assigned to Arm(s): weight loss surgery | Intervention Type: BEHAVIORAL; Name: weight management program; Assigned to Arm(s): Lifestyle Intervention
C: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Other: Exercise | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): Exercise
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Bardoxolone Methyl; Type: EXPERIMENTAL; Interventions: Drug: Bardoxolone Methyl: 20 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Bardoxolone Methyl: 20 mg; Assigned to Arm(s): Bardoxolone Methyl

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, 12-Month, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Two Doses of J867 Versus Placebo in Subjects With Uterine Leiomyomata.
Brief Summary: The objective of this study is to determine the safety and effectiveness of asoprisnil in symptomatic women with abnormal uterine bleeding associated with uterine fibroids.


Options:
A: Arm Label: A (PGL4001 5 mg); Type: EXPERIMENTAL; Interventions: Drug: PGL4001 | Arm Label: B (PGL4001 10mg); Type: EXPERIMENTAL; Interventions: Drug: PGL4001 | Arm Label: C (GnRH-agonist); Type: ACTIVE_COMPARATOR; Interventions: Drug: leuprorelin | Intervention Type: DRUG; Name: PGL4001; Assigned to Arm(s): A (PGL4001 5 mg), B (PGL4001 10mg) | Intervention Type: DRUG; Name: leuprorelin; Assigned to Arm(s): C (GnRH-agonist)
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: PGL4001, placebo, drug free period | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: PGL4001, progestin, drug free period | Intervention Type: DRUG; Name: PGL4001, placebo, drug free period; Assigned to Arm(s): A | Intervention Type: DRUG; Name: PGL4001, progestin, drug free period; Assigned to Arm(s): B
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Asoprisnil | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Asoprisnil | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Asoprisnil; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Asoprisnil; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Asoprisnil | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Asoprisnil | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Asoprisnil; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Asoprisnil; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH)
Brief Summary: The purpose of this study is to determine if orlistat (Xenical) therapy in overweight patients with NASH leads to enhanced weight loss over time, with subsequent improvement in the underlying necroinflammatory and fibrotic changes that are typical of NASH.


Options:
A: Arm Label: Liraglutide; Type: EXPERIMENTAL; Interventions: Drug: Liraglutide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Liraglutide-placebo | Intervention Type: DRUG; Name: Liraglutide; Assigned to Arm(s): Liraglutide | Intervention Type: OTHER; Name: Liraglutide-placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: Orlistat (Xenical); Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: 1400 kcal diet (30% fat); Assigned to Arm(s): N/A
C: Arm Label: Polypill; Type: EXPERIMENTAL; Interventions: Drug: Polypill | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Polypill; Assigned to Arm(s): Polypill
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pioglitazone | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin E | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Matching placebo | Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin E; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Matching placebo; Assigned to Arm(s): 3

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, Randomized, Double-Blind, Parallel Group Study to Evaluate the Safety and Efficacy of Asoprisnil (J867) in Patients With Uterine Leiomyomata.
Brief Summary: This study was designed to determine the safety and effectiveness of 3 asoprisnil doses compared to placebo, taken for 12 weeks by women with uterine fibroids.


Options:
A: Arm Label: Mifepristone 2.5 mg daily for three months; Type: EXPERIMENTAL; Interventions: Drug: Oral administration of mifepristone 2.5 mg daily for three months | Arm Label: Mifepristone 5 mg daily for three months; Type: EXPERIMENTAL; Interventions: Drug: Oral administration of mifepristone 5 mg daily for three months | Intervention Type: DRUG; Name: Oral administration of mifepristone 2.5 mg daily for three months; Assigned to Arm(s): Mifepristone 2.5 mg daily for three months | Intervention Type: DRUG; Name: Oral administration of mifepristone 5 mg daily for three months; Assigned to Arm(s): Mifepristone 5 mg daily for three months
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: PGL4001, placebo | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: PGL4001, progestin | Intervention Type: DRUG; Name: PGL4001, placebo; Assigned to Arm(s): A | Intervention Type: DRUG; Name: PGL4001, progestin; Assigned to Arm(s): B
C: Arm Label: Mifepristone; Type: EXPERIMENTAL; Interventions: Drug: Mifepristone | Arm Label: Inert capsule; Type: PLACEBO_COMPARATOR; Interventions: Drug: Inert Capsule | Intervention Type: DRUG; Name: Mifepristone; Assigned to Arm(s): Mifepristone | Intervention Type: DRUG; Name: Inert Capsule; Assigned to Arm(s): Inert capsule
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Asoprisnil | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Asoprisnil | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Asoprisnil | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Asoprisnil; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Asoprisnil; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Asoprisnil; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Multi-national, Multi-centre, Open Label, Safety Study to Assess the Safety of Chronic Therapy With the Humanised Anti-TNF PEG Conjugate CDP870 400 mg sc, (Dosed 4-weekly), in the Treatment of Patients With Active Crohn's Disease Who Have Previously Completed Studies CDP870-031 or CDP870-032
Brief Summary: An open-label follow-on safety study of CDP870 (400 mg every 4 weeks) in patients with Crohn's Disease who have completed a 26-week blinded study (CDP870-031 \[NCT00152490\] or CDP870-032 \[NCT00152425\]).


Options:
A: Intervention Type: DRUG; Name: Certolizumab Pegol (CDP870); Assigned to Arm(s): N/A
B: Arm Label: Certolizumab pegol; Type: EXPERIMENTAL; Interventions: Biological: certolizumab pegol (CDP870, CZP) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: BIOLOGICAL; Name: certolizumab pegol (CDP870, CZP); Assigned to Arm(s): Certolizumab pegol | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: CDP870 400 mg; Type: EXPERIMENTAL; Interventions: Biological: Certolizumab pegol | Intervention Type: BIOLOGICAL; Name: Certolizumab pegol; Assigned to Arm(s): CDP870 400 mg
D: Arm Label: Certolizumab Pegol; Type: EXPERIMENTAL; Interventions: Biological: Certolizumab Pegol (CDP870) | Intervention Type: BIOLOGICAL; Name: Certolizumab Pegol (CDP870); Assigned to Arm(s): Certolizumab Pegol

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Multi-center, Double-blind, Placebo-controlled, Parallel Group 24-Week Study to Assess the Efficacy and Safety of Two Dose Regimens of Liquid Certolizumab Pegol as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis Who Have an Incomplete Response to Methotrexate.
Brief Summary: A 24 week study in which patients are given study medication and assessed for signs and symptoms of rheumatoid arthritis. X-rays are performed to assess the progress of joint damage during the study.


Options:
A: Intervention Type: DRUG; Name: CDP870; Assigned to Arm(s): N/A
B: Arm Label: Certolizumab Pegol; Type: EXPERIMENTAL; Interventions: Biological: Certolizumab Pegol | Intervention Type: BIOLOGICAL; Name: Certolizumab Pegol; Assigned to Arm(s): Certolizumab Pegol
C: Intervention Type: DRUG; Name: Certolizumab Pegol; Assigned to Arm(s): N/A
D: Arm Label: PBO + MTX; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: methotrexate (MTX) | Arm Label: CZP + MTX; Type: EXPERIMENTAL; Interventions: Drug: CZP, Drug: methotrexate (MTX) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): PBO + MTX | Intervention Type: DRUG; Name: CZP; Assigned to Arm(s): CZP + MTX | Intervention Type: DRUG; Name: methotrexate (MTX); Assigned to Arm(s): CZP + MTX, PBO + MTX

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Multi-center, Double-blind, Placebo-controlled, Parallel Group 24-Week Study to Assess the Efficacy and Safety of Two Dose Regimens of Liquid Certolizumab Pegol as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis Who Have an Incomplete Response to Methotrexate.
Brief Summary: A 24 week study in which patients are given study medication and assessed for signs and symptoms of rheumatoid arthritis. X-rays are performed to assess the progress of joint damage during the study.


Options:
A: Arm Label: Adalimumab; Type: EXPERIMENTAL; Interventions: Biological: Adalimumab, Drug: Methotrexate placebo | Arm Label: Adalimumab + methotrexate; Type: EXPERIMENTAL; Interventions: Biological: Adalimumab, Drug: Methotrexate | Arm Label: Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: Methotrexate, Biological: Adalimumab placebo | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Adalimumab, Adalimumab + methotrexate | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Adalimumab + methotrexate, Methotrexate | Intervention Type: BIOLOGICAL; Name: Adalimumab placebo; Assigned to Arm(s): Methotrexate | Intervention Type: DRUG; Name: Methotrexate placebo; Assigned to Arm(s): Adalimumab
B: Intervention Type: DRUG; Name: CDP870; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Certolizumab Pegol; Assigned to Arm(s): N/A
D: Arm Label: Abatacept + Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: Abatacept, Drug: Methotrexate | Arm Label: Placebo + Methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate, Drug: Placebo | Arm Label: Abatacept + Methotrexate Open Label; Type: EXPERIMENTAL; Interventions: Drug: Abatacept, Drug: Methotrexate | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept + Methotrexate, Abatacept + Methotrexate Open Label | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Abatacept + Methotrexate, Abatacept + Methotrexate Open Label, Placebo + Methotrexate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Methotrexate

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Multi-center, Open-label, Follow-up Study, to Assess the Safety and Efficacy of Liquid Certolizumab Pegol as Additional Medication to Methotrexate, in the Treatment of Signs and Symptoms and in the Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis Who Participated in Study CDP870-050
Brief Summary: An open ended study in which patients who completed the preceding double-blind study NCT00160602 are given Certolizumab Pegol and assessed for signs and symptoms of Rheumatoid Arthritis.


Options:
A: Arm Label: Placebo followed by Certolizumab Pegol (CZP); Type: OTHER; Interventions: Other: Placebo, Biological: Certolizumab Pegol (CZP) 200 mg, Biological: Certolizumab Pegol (CZP) 400 mg | Arm Label: Certolizumab Pegol (CZP); Type: EXPERIMENTAL; Interventions: Biological: Certolizumab Pegol (CZP) 200 mg, Biological: Certolizumab Pegol (CZP) 400 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo followed by Certolizumab Pegol (CZP) | Intervention Type: BIOLOGICAL; Name: Certolizumab Pegol (CZP) 200 mg; Assigned to Arm(s): Certolizumab Pegol (CZP), Placebo followed by Certolizumab Pegol (CZP) | Intervention Type: BIOLOGICAL; Name: Certolizumab Pegol (CZP) 400 mg; Assigned to Arm(s): Certolizumab Pegol (CZP), Placebo followed by Certolizumab Pegol (CZP)
B: Arm Label: CDP870 200mg; Type: EXPERIMENTAL; Interventions: Drug: CDP870 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo of CDP870 | Intervention Type: DRUG; Name: CDP870; Assigned to Arm(s): CDP870 200mg | Intervention Type: DRUG; Name: Placebo of CDP870; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: Certolizumab Pegol; Assigned to Arm(s): N/A
D: Arm Label: Certolizumab Pegol; Type: EXPERIMENTAL; Interventions: Biological: Certolizumab Pegol | Intervention Type: BIOLOGICAL; Name: Certolizumab Pegol; Assigned to Arm(s): Certolizumab Pegol

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: ESPRIT: European/Australasian Stroke Prevention in Reversible Ischaemia Trial
Brief Summary: The objective of ESPRIT was to compare the efficacy and safety of mild anticoagulation or a combination treatment of aspirin and dipyridamole with the efficacy and safety of treatment with aspirin alone after cerebral ischemia of arterial origin.


Options:
A: Intervention Type: DRUG; Name: anticoagulation; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: aspirin and dipyridamole; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: aspirin alone; Assigned to Arm(s): N/A
B: Arm Label: polypill; Type: EXPERIMENTAL; Interventions: Drug: polypill | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Usual cardiovascular medications | Intervention Type: DRUG; Name: polypill; Assigned to Arm(s): polypill | Intervention Type: DRUG; Name: Usual cardiovascular medications; Assigned to Arm(s): Usual Care
C: Arm Label: ticagrelor; Type: EXPERIMENTAL; Interventions: Drug: ticagrelor | Arm Label: Acetylsalicylic acid (ASA); Type: ACTIVE_COMPARATOR; Interventions: Drug: Acetylsalicylic acid (ASA) | Intervention Type: DRUG; Name: ticagrelor; Assigned to Arm(s): ticagrelor | Intervention Type: DRUG; Name: Acetylsalicylic acid (ASA); Assigned to Arm(s): Acetylsalicylic acid (ASA)
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Best medical therapy | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Device: STARFlex septal closure system | Intervention Type: DEVICE; Name: STARFlex septal closure system; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Best medical therapy; Assigned to Arm(s): 1

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter Randomized Controlled Trial of Antibiotic Treatment in Children With Urinary Tract Infections: Oral Amoxicillin/Clavulanic Acid vs Initial iv Ceftriaxone.
Brief Summary: The main objectives of the study are

1. to compare the efficacy of oral vs initial iv antibiotic treatment in children with a first episode of UTI
2. to assess the diagnostic power of the various imaging technique (renal ultrasonogram, voiding cystourethrogram, and renal scanning with technetium-99m-labeled dimercaptosuccinic acid)


Options:
A: Intervention Type: DRUG; Name: oral amoxicilline/clavulanic acid; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: iv ceftriaxone; Assigned to Arm(s): N/A
B: Arm Label: sulfamethoxazole/trimethoprim; Type: EXPERIMENTAL; Interventions: Drug: Sulfamethoxazole/trimethoprim | Arm Label: No prophylaxis; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Sulfamethoxazole/trimethoprim; Assigned to Arm(s): sulfamethoxazole/trimethoprim
C: Arm Label: Trimethoprim-Sulfamethoxazole; Type: ACTIVE_COMPARATOR; Interventions: Drug: Trimethoprim-Sulfamethoxazole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Trimethoprim-Sulfamethoxazole; Assigned to Arm(s): Trimethoprim-Sulfamethoxazole | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: antibiotic to reduce the recurrence of infection; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter Randomized Controlled Trial of Antibiotic Treatment in Children With Urinary Tract Infections: Oral Amoxicillin/Clavulanic Acid vs Initial iv Ceftriaxone.
Brief Summary: The main objectives of the study are

1. to compare the efficacy of oral vs initial iv antibiotic treatment in children with a first episode of UTI
2. to assess the diagnostic power of the various imaging technique (renal ultrasonogram, voiding cystourethrogram, and renal scanning with technetium-99m-labeled dimercaptosuccinic acid)


Options:
A: Intervention Type: DRUG; Name: antibiotic to reduce the recurrence of infection; Assigned to Arm(s): N/A
B: Arm Label: Trimethoprim-Sulfamethoxazole; Type: ACTIVE_COMPARATOR; Interventions: Drug: Trimethoprim-Sulfamethoxazole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Trimethoprim-Sulfamethoxazole; Assigned to Arm(s): Trimethoprim-Sulfamethoxazole | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: oral amoxicilline/clavulanic acid; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: iv ceftriaxone; Assigned to Arm(s): N/A
D: Arm Label: sulfamethoxazole/trimethoprim; Type: EXPERIMENTAL; Interventions: Drug: Sulfamethoxazole/trimethoprim | Arm Label: No prophylaxis; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Sulfamethoxazole/trimethoprim; Assigned to Arm(s): sulfamethoxazole/trimethoprim

Answer: C